

PRODUCT INFORMATION




Fimasartan

Item No. 36524

CAS Registry No.: 247257-48-3
Formal Name: 2-butyl-1,6-dihydro-N,N,4-trimethyl-6-oxo-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-pyrimidineethanethioamide

Synonym: BR-A-657
MF: C₂₇H₃₁N₇OS
FW: 501.6
Purity: ≥98%
UV/Vis.: λ_{max}: 262 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Fimasartan is supplied as a solid. A stock solution may be made by dissolving the fimasartan in the solvent of choice, which should be purged with an inert gas. Fimasartan is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of fimasartan in these solvents is approximately 0.5, 20, and 10 mg/ml, respectively.

Description

Fimasartan is an antagonist of the angiotensin II type 1 (AT₁) receptor (IC₅₀ = 0.16 nM in HEK293 cells expressing the human receptor).¹ It is selective for the AT₁ over the AT₂ receptor (IC₅₀ = 69 μM). Fimasartan (62.5, 125, and 250 μM) inhibits LPS-induced increases in inducible nitric oxide synthase (iNOS) levels and NO production, as well as NF-κB nuclear translocation in RAW 264.7 macrophages.² It reduces angiotensin II-induced contractions of isolated rabbit aortic rings in a concentration-dependent manner.¹ *In vivo*, fimasartan decreases mean arterial pressure in rats with hypertension induced by furosemide (Item No. 17273) and renal hypertensive rats when administered at doses of 10 and 0.3 mg/kg, respectively. Formulations containing fimasartan have been used in the treatment of hypertension.

References

1. Chi, Y.H., Lee, J.H., Kim, J.H., *et al.* Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist. *Biol. Pharm. Bull.* **36(7)**, 1208-1215 (2013).
2. Ryu, S., Shin, J.-S., Cho, Y.-W., *et al.* Fimasartan, anti-hypertension drug, suppressed inducible nitric oxide synthase expressions via nuclear factor-kappa B and activator protein-1 inactivation. *Biol. Pharm. Bull.* **36(3)**, 467-474 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/10/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM